L-Malic acid
|
Basic information |
| Metabolite name | L-Malic acid |
 | HMDB0000156 |
 |
C00149 |
 |
222656 |
| Synonyms | malate; |
| No. of studies | 39 |
|
Basic information |
| Metabolite name | L-Malic acid |
| HMDB0000156 |
|
C00149 |
|
222656 |
| Synonyms | malate; |
| No. of studies | 39 |
|
Relationship between L-Malic acid and depression (count: 39) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M033 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Down |
| Study M050 | Type3 | 14h Ketamine group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M050 | Type3 | 2h Ketamine group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M071 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | C57BL/6N mouse | Up |
| Study M098 | Type1 | depressed group vs. control group | Peripheral blood mononuclear cell | Human | Down |
| Study M1019 | Type1 | depression group vs. control group | Serum | Human | Down |
| Study M1032 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M1039 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M1045 | Type1 | depression group vs. control group | Plasma | Human | Up |
| Study M105 | Type1 | sCSDS group vs. control group | Liver | C57BL/6JJmsSlc mouse | Up |
| Study M1074 | Type1 | MDD group vs. control group | Serum | Human | Down |
| Study M1075 | Type1 | CSDS group vs. control group | Serum | C57BL/6J mouse | Down |
| Study M1075 | Type1 | CSDS group vs. control group | Frontal cortex | C57BL/6J mouse | Down |
| Study M1097 | Type1 | placebo-treated depression group vs. control group | Faece | Human | Up |
| Study M1143 | Type2 | MDD group, after 2-week escitalopram treatment vs. baseline | Plasma | Human | Up |
| Study M129 | Type3 | venlafaxine group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M207 | Type1 | depressed group vs. control group | Hippocampus | Kunming mouse | Up |
| Study M208 | Type1 | GCI model group vs. control group | Hippocampus | ICR mouse | Up |
| Study M463 | Type3 | venlafaxine group vs. control group | Prefrontal cortex | C57BL/6J mouse | Down |
| Study M478 | Type3 | ketamine group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M512 | Type1 | CUMS group vs. control group | Urine | Goto-Kakizaki rat | Down |
| Study M547 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M614 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M617 | Type1 | CUMS group vs. control group | Serum | C57BL/6 mouse | Up |
| Study M631 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Down |
| Study M631 | Type2 | CUMS + high dose of iridoid-rich fraction of V. jatamansi group vs. CUMS group | Serum | Kunming mouse | Up |
| Study M633 | Type1 | corticosterone group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M648 | Type1 | ART-treated HIV with depressive symptom group vs. ART-treated HIV without depressive symptom group, discovery cohort | Plasma | Human | Up |
| Study M712 | Type1 | depression group vs. control group | Prefrontal cortex | Cynomolgus monkey | Down |
| Study M712 | Type1 | depression group vs. control group | Intestine | Cynomolgus monkey | Up |
| Study M762 | Type1 | corticosterone group vs. control group | Liver | Wistar rat | Down |
| Study M772 | Type1 | CUMS group vs. control group | Amygdala | Sprague-Dawley rat | Down |
| Study M788 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M790 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M790 | Type2 | CUMS + venlafaxine group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M790 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M840 | Type1 | A1/A2 beta-casein group vs. control group | Urine | Wistar rat | Down |
| Study M844 | Type1 | CORT group vs. control group | PC12 cell | Rat | Up |
| Study M846 | Type2 | postpartum depression model + 919 syrup group vs. postpartum depression model group | Hippocampus | BALB/c mouse | Down |
| Study M883 | Type1 | MDD group vs. control group | Blood | Human | Up |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M953 | Type1 | CRS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M966 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M966 | Type2 | CUMS + venlafaxine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M966 | Type2 | CUMS + Xiaoyao San group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M975 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M975 | Type2 | CUMS + low dose of Yang-Xin-Jie-Yu Decoction group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M975 | Type2 | CUMS + middle dose of Yang-Xin-Jie-Yu Decoction group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M981 | Type1 | Abeta oligomer group vs. control group | Serum | ICR mouse | Down |
| Study M981 | Type2 | Abeta oligomer + involuntary and voluntary running + acousto-optic stimulation group vs. Abeta oligomer group | Serum | ICR mouse | Up |
| Study M981 | Type2 | Abeta oligomer + involuntary and voluntary running group vs. Abeta oligomer group | Serum | ICR mouse | Up |
| Study M981 | Type2 | Abeta oligomer + acousto-optic stimulation group vs. Abeta oligomer group | Serum | ICR mouse | Up |